NCT02917005: A Phase II Study of Ovarian Function Suppression and Exemestane with or without Palbociclib in Premenopausal Women with ER Positive/HER-2 Negative Metastatic Breast Cancer. This evidence concerns the gene ESR1 and breast cancer.